Celltrion's Herzuma (biosimilar- trastuzumab) Overtook the Original Treatments for Cancer
Shots:
- Herzuma wins <51% of the market share in Japan in Jun’21 & secured the top position with the reliability proved by the expanding prescriptions globally. Celltrion is co-promoting Herzuma along with Nippon Kayaku
- Celltrion also mentioned the Japanese government's policy change as another factor to affect Herzuma prescription positively. Tokyo has added a policy to promote biosimilar drugs in Prime Minister Yoshihide Suga's Honbebuto Paper in Jun’21
- Celltrion has declared the bids for Herzuma & Truxima in Brazil and Japan. The company plans to launch Remsima (infliximab) & Yuflyma (adalimumab)
| Ref: Businesswire | Image: Celltrion
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com